A strain of Bacillus velez with broad-spectrum antibacterial activity and its application in bacteriocin production
By isolating Bacillus CM7-4 strain and its bacteriocin PCM7-4 from seawater, the problem of poor inhibition of food-borne pathogenic bacteria in the prior art is solved, and a variety of pathogenic bacteria are achieved Effective inhibition, especially Listeria monocytogenes, has important public health safety significance.
Patent Information
- Application Number
- CN202411171957.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The prior art lacks antibacterial agents that can effectively inhibit foodborne pathogenic bacteria, especially the inhibitory effect of Listeria monocytogenes is not ideal, resulting in food safety problems, and the development and utilization of marine microorganisms are not yet sufficient.
Isolated and identified a Bacillus velezensis CM7-4 strain and its novel bacteriological protein PCM7-4 from seawater. It has broad-spectrum antibacterial activity and can effectively inhibit a variety of pathogenic bacteria, including E. coli. , Pseudomonas aeruginosa, Salmonella, Enterobacter aerobic, Pasteurella polyococci, Enterococcus faecalis and Listeria monocytogenes.
Bacterikin PCM7-4 has a significant inhibitory effect on Listeria monocytogenes, which can affect the formation of its biofilm and the biosynthesis of secondary metabolites, and provides a novel antibacterial drug to control pathogens in public health safety.
Smart Images

Figure CN118726204B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of microbial technology, and more specifically, relates to a strain of Bacillus velezine with broad-spectrum antibacterial activity and its application in producing bacteriocin. Background Art
[0002] As the difficulty of drug research and development from terrestrial resources continues to increase, the "blue ocean drug library" has become an important direction of modern medical research. At present, through the development and utilization of marine natural products, some substances with excellent active effects have been studied. These substances not only have pharmacological activity, but also have good effects, and have fewer or even no side effects. There are also many kinds of microorganisms in the ocean, but the development and utilization of marine microorganisms is still relatively small, and there are still many unknown products that have not been discovered. Therefore, the research and development of marine natural products has important research significance.
[0003] Foodborne pathogens are pathogenic bacteria that can cause food poisoning or spread through food. Pathogenic bacteria directly or indirectly contaminate food and water sources. Oral infection of livestock and poultry and humans can lead to the occurrence of intestinal infectious diseases and food poisoning as well as the spread of livestock and poultry infectious diseases. Foodborne pathogens are an important source of food safety problems, seriously affecting the health and development of livestock and poultry and humans. Common food pathogens mainly include Escherichia coli ( Escherichia coli ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ),salmonella( salmonella )、Enterobacter aerogenes( Enterobacter aerogenes ), Pasteurella multocida ( Pasteurellamultocida ), Enterococcus faecalis ( Enterococcus faecalis ), Staphylococcus aureus ( Staphylococcus aureus ) and Listeria monocytogenes ( Listeria monocytogenes ), etc. However, there is still a lack of antimicrobial agents that can effectively inhibit these pathogenic bacteria, and due to the strong activity of some pathogenic bacteria, the inhibition effect of existing antimicrobial agents is not ideal; such as Listeria monocytogenes, a zoonotic pathogen that can survive for a long time in soil, feces, silage and hay, has strong resistance to alkali and salt, and can still survive at 4°C. It is a foodborne pathogen that seriously affects public health, so there is an urgent need to find more highly effective new antimicrobial drugs.
[0004] Bacteriocin is a polypeptide or precursor polypeptide with antibacterial activity, which is synthesized by bacteria through ribosomes and has the effect of destroying biofilm. Up to now, in the research on the separation and identification of bacteriocins at home and abroad, there is no report on the isolation of bacteriocins with antibacterial activity from seawater. Certain natural active substances produced by Bacillus, especially antimicrobial peptides, have attracted much attention because of their good antibacterial effect and high efficiency. However, there are still few Bacillus with broad-spectrum antibacterial activity and the ability to produce bacteriocins. It is necessary to develop new bacteriocins from more sources as natural food antibacterial additives or antibacterial drugs to control pathogenic bacteria, especially for the pollution of Listeria monocytogenes, which is of great significance to public health and safety. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the shortage of existing microbial strain resources with broad-spectrum antibacterial activity and capable of producing bacteriocin, and to provide a strain of Bacillus velezine with broad-spectrum antibacterial activity and its application in producing bacteriocin.
[0006] The present invention aims to provide a strain of Bacillus Velezii ( Bacillus velezensis ) CM7-4 strain.
[0007] Another object of the present invention is to provide the application of Bacillus Velez CM7-4 strain.
[0008] Another object of the present invention is to provide a bacteriostatic agent.
[0009] Another object of the present invention is to provide a bacteriocin.
[0010] Another object of the present invention is to provide the use of bacteriocin.
[0011] The above-mentioned purpose of the present invention is achieved through the following technical solutions:
[0012] The present invention provides a strain of Bacillus Velezii ( Bacillus velezensis ) CM7-4 strain, which was deposited in the Guangdong Provincial Microbiological Culture Collection Center on July 16, 2024, with the collection number GDMCC No: 64872, and the collection address is 5th Floor, Building 59, 100 Compound, Xianlie Middle Road, Guangzhou.
[0013] The present invention isolates and identifies a strain of Bacillus Velezii CM7-4 from seawater. The colony of the strain is milky white, round, smooth, slightly convex, 1.0-1.5 mm, and viscous. It is a Gram-positive bacterium. Studies have shown that the CM7-4 strain has a broad-spectrum antibacterial activity and can inhibit a variety of pathogenic bacteria, especially Escherichia coli ( Escherichia coli ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ),salmonella( salmonella )、Enterobacter aerogenes( Enterobacter aerogenes), Pasteurella multocida ( Pasteurellamultocida ), Enterococcus faecalis ( Enterococcus faecalis ), Staphylococcus aureus ( Staphylococcus aureus ) and Listeria monocytogenes ( Listeria monocytogenes ) have good antibacterial effects. At the same time, a new bacteriocin was isolated from the CM7-4 strain, named PCM7-4. The bacteriocin PCM7-4 was purified and determined by acid precipitation, TA-GF75 gel chromatography, Tiderose Q HP anion chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC). The results showed that the molecular weight of bacteriocin PCM7-4 was 14.3 KDa, it was heat-resistant, highly stable in the pH range of 2-12, sensitive to proteinase K, and had no hemolytic activity; and bacteriocin PCM7-4 had a significant inhibitory effect on Listeria monocytogenes, with an MIC of 5.625μg / mL for Listeria monocytogenes, which could inhibit its biofilm formation; further transcriptome analysis and verification showed that bacteriocin PCM7-4 mainly affected the biosynthesis of secondary metabolites of Listeria monocytogenes, the expression of genes related to the phosphorus transferase system (PTS), starch and sucrose metabolism. Therefore, the Bacillus Velezii provided by the present invention has a broad-spectrum antibacterial activity and can produce bacteriocins, thus providing a method for preparing more and more effective antibacterial drugs.
[0014] Therefore, the present invention provides the use of the Bacillus Velez CM7-4 strain or its bacterial solution in the preparation of bacteriocin.
[0015] The present invention provides application of Bacillus Velezii CM7-4 strain or bacterial liquid thereof in inhibiting pathogenic bacteria for non-disease diagnosis and treatment purposes.
[0016] Furthermore, the pathogenic bacteria are one or more of Escherichia coli, Pseudomonas aeruginosa, Salmonella, Enterobacter aerogenes, Pasteurella multocida, Enterococcus faecalis, Staphylococcus aureus, and Listeria monocytogenes.
[0017] The present invention provides application of Bacillus Velezii CM7-4 strain or its bacterial solution in preparing an antibacterial agent.
[0018] The invention provides an antibacterial agent, which contains the Velezella CM7-4 strain or its bacterial liquid.
[0019] Preferably, the bacterial liquid is fermentation supernatant.
[0020] More preferably, the fermentation supernatant is extracted by acid precipitation to obtain a crude bacteriocin extract, and the concentration of the crude bacteriocin extract is not less than 230 μg / mL.
[0021] The invention provides a bacteriocin, which is prepared from the Bacillus Velezii CM7-4 strain or its bacterial liquid and has a molecular weight of 14.3 KDa.
[0022] The present invention provides the use of bacteriocin in the fight against Listeria monocytogenes for the purpose of non-disease diagnosis and treatment.
[0023] The invention provides application of bacteriocin in preparing antibacterial drugs.
[0024] The present invention has the following beneficial effects:
[0025] The present invention isolates and identifies a strain of Bacillus Velezii ( Bacillus velezensis ) CM7-4 strain, which has a broad-spectrum antibacterial activity and can inhibit a variety of pathogenic bacteria. It has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, Salmonella, Enterobacter aerogenes, Pasteurella multocida, Enterococcus faecalis, Staphylococcus aureus and Listeria monocytogenes; at the same time, a new bacteriocin was isolated from the CM7-4 strain, named PCM7-4. Through purification and determination, the molecular weight of bacteriocin PCM7-4 was 14.3 KDa, it is heat-resistant, highly stable in the pH range of 2-12, sensitive to proteinase K, and has no hemolytic activity. In addition, bacteriocin PCM7-4 has a significant inhibitory effect on Listeria monocytogenes, with an MIC of 5.625 μg / mL for Listeria monocytogenes, and can inhibit the formation of Listeria monocytogenes biofilm; further transcriptome analysis and verification showed that bacteriocin PCM7-4 mainly affects the biosynthesis of secondary metabolites of Listeria monocytogenes, the expression of genes related to the phosphorus transferase system (PTS), and starch and sucrose metabolism; therefore, the Bacillus Velez CM7-4 strain provided by the present invention and the bacteriocin PCM7-4 prepared therefrom are new antibacterial drugs, which are of great significance to public health safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is the result of the circular evolutionary tree based on 16S rRNA.
[0027] Figure 2 This is the result of gel chromatography of TA-GF75.
[0028] Figure 3 This is the result of Tiderose Q HP anion chromatography.
[0029] Figure 4 This is a diagram of the RP-HPLC purification results.
[0030] Figure 5 This is a diagram of the SDS-PAGE analysis results.
[0031] Figure 6 The stability diagram of bacteriocin PCM7-4 ( Figure 6 A in it is temperature stability, Figure 6 B is pH stability, Figure 6 C in the figure represents enzyme stability).
[0032] Figure 7 This is the hemolytic result of bacteriocin PCM7-4.
[0033] Figure 8 This is the growth curve of Listeria monocytogenes induced by bacteriocin PCM7-4.
[0034] Fig. 9 This is the result of scanning electron microscopy observation of the effect of bacteriocin PCM7-4 on Listeria monocytogenes biofilm.
[0035] Fig.10 Volcano plot of differentially expressed genes.
[0036] Fig.11 This is the result of GO enrichment analysis.
[0037] Fig.12 This is a KEGG enrichment scatter plot.
[0038] Fig.13 The relative expression results of the target gene verified by RT-qPCR ( Fig.13 The A in the figure indicates genes with increasing differential order; Fig.13 B in the figure indicates genes with decreasing order of difference). DETAILED DESCRIPTION
[0039] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0040] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0041] Example 1 Isolation, purification and identification of strains
[0042] After diluting 50 mL of seawater sample 10 times with ultrapure water, evenly spread it on M10 medium (including 10.0 g soluble starch, 0.5 g hydrolyzed casein, 10 mL complex salt mother solution, 14.0 g agar, and 1000 mL deionized water), cultured at 28°C for 48 h, picked a single colony and placed it in LB liquid medium (including 10.0 g tryptone, 5.0 g yeast powder, 10.0 g sodium chloride, and 1000 mL deionized water), purified it, added 30% glycerol and stored it at -80°C.
[0043] The solid agar punching method was used to screen out bacteria with antibacterial activity. Specifically, Listeria monocytogenes ATCC 19115 was inoculated at a 1% inoculum into unsolidified LB solid medium (including 10.0 g of tryptone, 5.0 g of yeast powder, 10.0 g of sodium chloride, 15.0 g of agar, and 1000 mL of deionized water). After solidification, holes were punched with a sterile puncher. Subsequently, the single colony to be tested isolated above was inoculated into LB liquid medium and cultured overnight at 37°C. 200 μL of the test bacterial solution was added to the well to determine its antibacterial activity.
[0044] The strain with obvious antibacterial activity against Listeria monocytogenes after the initial screening was named CM7-4 strain, and the CM7-4 strain was incubated in M10 solid medium at 28°C for 48 h. After the strain was purified, a single colony was selected for whole-genome sequencing, and the bacteria were identified by 16S rRNA sequencing. The sequencing results were used to construct a phylogenetic tree using FastTree software.
[0045] The phylogenetic tree constructed is as follows Figure 1 As shown, the 16S rDNA sequence of the CM7-4 strain isolated and identified by the present invention is similar to that of Bacillus Velezii ( Bacillus velezensis ) have a high homology. Based on the morphological characteristics of the strain and the results of molecular biological identification, the taxonomic status of the CM7-4 strain was identified as Bacillus ( Bacillus ) Bacillus velezensis ) strain, the strain name is CM7-4 strain, and it was deposited in Guangdong Provincial Microbiological Culture Collection Center on July 16, 2024, with the collection number GDMCC No: 64872, and the collection address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.
[0046] Example 2 Antibacterial activity of Bacillus velez CM7-4
[0047] 1. Preparation of fermentation supernatant of Bacillus Velez CM7-4
[0048] Bacillus Velez CM7-4 was inoculated in LB broth and cultured at 37℃ for 16 h, and then inoculated into fermentation medium (including 4.0 g glucose, 0.5 g beef extract, 0.5 g yeast extract, 1.5 g peptone, 0.02 g NaH2PO4·2H2O, 0.05 g Na2HPO4·2H2O, 0.05 g Mg2SO4·7H2O, 0.02 g CaCl2, 0.02 g MnSO4, 100 mL distilled water) at a 2% inoculum, cultured at 30℃, 180 rpm for 24 h, centrifuged at 8000 rpm for 30 min at 4℃, and the fermentation supernatant was collected and sterilized by filtration through a 0.22 μm filter membrane to obtain a cell-free supernatant. The cell-free supernatant was adjusted to pH 2.0 with 6 mol / L HCl, allowed to stand at 4℃ overnight, and then centrifuged at 4℃, 8000 rpm for 30 min to collect the precipitate. After the precipitate was redissolved with PBS, it was sterilized by filtration through a 0.22 μm filter membrane to obtain a crude bacteriocin extract, the concentration of which was 230 μg / mL.
[0049] 2. Antibacterial spectrum
[0050] The solid agar punch method was used to determine the activity of crude bacteriocin extract against Escherichia coli ( Escherichia coli )CMCC (B) 44103, Pseudomonas aeruginosa ( Pseudomonas aeruginosa )ATCC 9027, Salmonella ( salmonella )CMCC (B) 94, Enterobacter aerogenes ( Enterobacter aerogenes )ATCC 13048, Pasteurella multocida ( Pasteurellamultocida )CVCC 393, Enterococcus faecalis ( Enterococcus faecalis )ATCC 29212, Staphylococcus aureus ( Staphylococcus aureus ) ATCC 25923 and Listeria monocytogenes ATCC 19115, and the diameter of the inhibition zone was measured by a vernier caliper.
[0051] The antibacterial results are shown in Table 1, which show that the crude bacteriocin extract of Bacillus Velez CM7-4 strain has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, Salmonella, Enterobacter aerogenes, Pasteurella multocida, Enterococcus faecalis, Staphylococcus aureus and Listeria monocytogenes. The CM7-4 strain has a broad spectrum, among which the antibacterial effect on Listeria monocytogenes is the best.
[0052] Table 1 Antibacterial effects of crude bacteriocin extracts on various bacteria
[0053]
[0054] Example 3 Isolation and Identification of Bacillus Velez CM7-4 Bacteriocin
[0055] 1. TA-GF75 dextran gel column purification
[0056] The crude bacteriocin extract prepared in Example 2 was loaded into a TA-GF75 gel column equilibrated with deionized water at a flow rate of 0.55 mL / min to obtain a purified protein. The antibacterial activity of the isolated protein was detected by the solid agar punching method using the same method as in Example 1, and the antibacterial activity of the crude bacteriocin extract was analyzed by TA-GF75 gel chromatography.
[0057] TA-GF75 gel chromatography results are as follows Figure 2 As shown, four peaks were obtained after chromatography, and the G3 peak was analyzed by solid agar punching method and showed obvious antibacterial activity.
[0058] 2. Tiderose Q HP anion column purification
[0059] The purified protein with antibacterial effect was loaded onto a Tiderose Q HP anion column balanced with 1 mol / L NaCl at a flow rate of 3 mL / min to obtain a concentrated protein; the antibacterial activity of the separated protein was detected by a solid agar punching method using the same method as in Example 1, and the concentrated protein was subjected to Tiderose Q HP anion chromatography to screen the peak with antibacterial effect and then concentrated and passed through the next column.
[0060] Tiderose Q HP anion chromatography results are as follows Figure 3 As shown, three peaks were obtained after Tiderose Q HP anion chromatography. The fractions corresponding to these peaks were collected and concentrated, and then the antibacterial effect was determined by the solid agar punching method, showing that the H3 peak had obvious antibacterial activity.
[0061] 3. Reverse-phase HPLC purification
[0062] The fractions corresponding to the H3 peak after anion column purification were concentrated and purified by reverse phase high performance liquid chromatography. The above separated protein was purified by RP-HPLC using a C18 column (5 μm, 4.6 mm × 250 mm) with water (containing 0.1% trifluoroacetic acid) and acetonitrile (containing 0.1% trifluoroacetic acid) as the mobile phases. The elution program was as follows: 0-10 min, 5% acetonitrile (containing 0.1% trifluoroacetic acid); 11-20 min, 5%-50% acetonitrile (containing 0.1% trifluoroacetic acid); 21-30 min, 50%-70% acetonitrile (containing 0.1% trifluoroacetic acid); 31-38 min, 70%-95% acetonitrile (containing 0.1% trifluoroacetic acid). The eluted fractions were concentrated, sterilized by 0.22 μm filter membrane, and then the antibacterial activity was determined by solid agar punching method.
[0063] RP-HPLC purification results are as follows Figure 4 As shown, three peaks were obtained in the chromatogram. The fractions corresponding to the peaks were collected and concentrated, and then the antibacterial effect was determined by the solid agar punching method, which showed that R1 had significant antibacterial activity.
[0064] 4. Estimation of molecular weight of bacteriocin by Tricine-SDS-PAGE
[0065] The solution of the bacteriocin of Bacillus velez CM7-4 purified by RP-HPLC was subjected to SDS-PAGE detection and analysis. The prepared gel was energized at 30 V for 1 h, electrophoresed at 100 V until the end, and the gel was stained with Coomassie Brilliant Blue. The molecular weight of the bacteriocin was estimated by SDS-PAGE electrophoresis.
[0066] The results of SDS-PAGE determination of the elution peak R1 after liquid phase purification are as follows: Figure 5 As shown, the molecular weight of the bacteriocin isolated and purified from Bacillus velez CM7-4 strain is 14.3 KDa, and it is named bacteriocin PCM7-4.
[0067] 5. Determination of bacteriocin PCM7-4 content
[0068] The protein content was determined by the Bradford kit method. The protein standard solution and PBS were used to prepare a gradient of 200μg / mL, 160μg / mL, 120μg / mL, 80μg / mL, 60μg / mL, 40μg / mL, 20μg / mL, and 0μg / mL protein standards. Take 20μL of the diluted protein standard solution and add it to a 96-well plate. Take two groups of parallels for each concentration and add 200mL of 1×G250 staining solution. Leave it at room temperature for 4 minutes and measure the absorbance at 570nm using an enzyme reader. According to the standard curve with protein concentration as the horizontal axis and absorbance as the vertical axis, the linear equation y=0.5172x-0.2341 and the linear correlation coefficient R were obtained. 2 =0.9906. Take 10 μL of Bacillus velezensis bacteriocin solution and dilute it 2 times, then add 200 μL of 1×G250 staining solution. Leave it at room temperature for 4 minutes, and measure the absorbance at 570 nm using an enzyme reader.
[0069] The concentration of Bacillus velez bacteriocin PCM7-4 was calculated by the linear equation to be 33.75 μg / mL.
[0070] Example 4 Properties of Bacillus velez bacteriocin PCM7-4
[0071] 1. Stability of bacteriocin PCM7-4
[0072] The temperature stability, pH stability and enzyme stability of bacteriocin PCM7-4 were determined. Bacteriocin PCM7-4 was placed in a water bath at 40 ℃, 60 ℃, 80 ℃, and 100 ℃ for 1 h, and high pressure at 121 ℃ for 15 min, and then cooled to room temperature; bacteriocin PCM7-4 was adjusted to pH 2, 4, 6, 8, 10, and 12, and adjusted to the original pH after overnight at 4 ℃; pepsin, proteinase K, trypsin, and papain were added to the sample at a final concentration of 1 mg / mL and incubated at 37 ℃ for 1 h. Untreated bacteriocin PCM7-4 was used as a blank control, and the antibacterial activity of the bacteriocin was determined by the solid agar punching method as in Example 1.
[0073] The effects of temperature, pH, and enzyme on the antibacterial activity of bacteriocin PCM7-4 are shown in the following table. Figure 6As shown, PCM7-4 has good stability. After treatment at 40℃-100℃, the antibacterial activity remains between 84.77%±0.57% and 86.30%±2.43%, and after treatment at 121℃ for 15 min, the antibacterial activity is still 76.40%±0.66%. Under acidic conditions of pH 2-6, the antibacterial activity of bacteriocin PCM7-4 remains between 88.43%±1.65% and 99.73%±0.46%, and under alkaline conditions of pH 8-12, the antibacterial activity remains between 69.17%±1.97% and 78.13%±2.06%. After treatment with trypsin, pepsin and papain, the antibacterial activity of bacteriocin PCM7-4 remains between 91.13%±0.93% and 99.87%±0.23%, and the antibacterial effect is lost after treatment with proteinase K.
[0074] 2. Hemolytic activity of bacteriocin PCM7-4
[0075] Prepare 7% (v / v) sheep blood agar plates, then add 200 μL of 2× MIC bacteriocin PCM7-4 samples to the respective wells and incubate at 37°C for 48 h. The negative control is PBS, and the positive control is 1% Triton X-100. No hemolytic zone is formed around the sample, indicating no hemolytic activity. On the contrary, a hemolytic zone is formed around it, indicating hemolytic activity.
[0076] The results are as follows Figure 7 As shown, compared with the positive control 1% Triton X-100, bacteriocin PCM7-4 did not show hemolytic zone and therefore was not hemolytic.
[0077] 3. Antibacterial effect of bacteriocin PCM7-4
[0078] (1) Minimum inhibitory concentration of bacteriocins against Listeria monocytogenes
[0079] The minimum inhibitory concentration (MIC) of bacteriocin PCM7-4 against Listeria monocytogenes was determined by the microbroth two-fold dilution method. The lowest concentration at which no bacterial growth was observed with the naked eye was defined as the MIC of the bacteriocin. The negative control was LB liquid culture medium without the addition of bacteriocin and bacterial solution, and the positive control was the bacterial solution of Listeria monocytogenes without the addition of bacteriocin.
[0080] The MIC of bacteriocin PCM7-4 against Listeria monocytogenes was measured to be 5.625 μg / mL.
[0081] (2) Growth curve of bacteriocin against Listeria monocytogenes
[0082] Listeria monocytogenes was inoculated into LB liquid medium and cultured overnight. Bacteriocin PCM7-4 was added to reach final concentrations of 1 / 8×MIC, 1 / 4×MIC, 1 / 2×MIC, 1×MIC and 2×MIC. Samples were collected at 0, 2, 4, 6 and 8 h, respectively, and OD was measured using a microplate reader. 600 value.
[0083] The growth curve of anti-Listeria monocytogenes Figure 8 As shown, when the addition amount of bacteriocin PCM7-4 was 1×MIC and 2×MIC, Listeria monocytogenes stopped growing at 2 to 8 hours. When the addition amount of bacteriocin PCM7-4 was 1 / 2×MIC and 1 / 4×MIC, the growth of Listeria monocytogenes at 2 to 8 hours was significantly inhibited compared with the control group.
[0084] (3) Effect of bacteriocin PCM7-4 on Listeria monocytogenes biofilm
[0085] The effect of bacteriocin PCM7-4 on Listeria monocytogenes biofilm was observed by scanning electron microscopy. A sterile cover slip (9 mm) was placed in a 48-well plate, and 1 mL of Listeria monocytogenes solution containing different concentrations of bacteriocin PCM7-4 (1 / 8MIC, 1 / 4MIC) was added to the 48-well plate and incubated at 37°C for 48 h. After the supernatant was removed, the sample was washed three times with PBS and fixed with 2.5% glutaraldehyde overnight at 4°C. After washing three times with PBS, the sample was dehydrated with a series of ethanol solutions of different concentrations (30, 50, 70, 85, 100%), dried with carbon dioxide, and then sprayed with gold, and finally observed with SEM (S-4800, JEOL, Japan).
[0086] The scanning electron microscopy results are as follows Fig. 9 As shown, the cells in the control group showed tight adhesion and aggregation. After treatment with 1 / 8 MICPCM7-4, the formation of the biofilm was destroyed and the cells showed loose aggregation. After treatment with 1 / 4 MIC PCM7-4, the formation of the biofilm was inhibited and the cells showed a dispersed state.
[0087] (4) Transcriptome analysis
[0088] Bacteriocin PCM7-4 was mixed with overnight cultured Listeria monocytogenes and its final concentration was adjusted to 1 / 2 times the MIC. After 6 hours of culture at 37°C, total RNA was extracted using Trizol reagent. The extracted RNA was then sent to a biotechnology company for sequencing and analysis using the Illumina sequencing platform. The test results were screened according to the significant difference criteria, and the significant differential expression and up- and down-regulation of genes were statistically analyzed.
[0089] The results of differentially expressed genes are as follows Fig.10As shown, a total of 103 genes were significantly changed, of which 72 genes were significantly down-regulated and 31 genes were significantly up-regulated.
[0090] The differentially expressed genes were mainly distributed in biological processes, with the largest number in the hosphoenolpyruvate-dependent sugar phosphotransferase system and methionine biosynthetic process. In terms of molecular function, the largest number was found in protein-N(PI)-phosphohistidine-sugar phosphotransferase activity. In addition, there were two differentially expressed genes in the cellular component-related ATP-binding cassette (ABC) transporter complex.
[0091] According to KEGG enrichment results Figure 11-12 It can be seen that the differentially expressed genes are mainly concentrated in biosynthesis of secondary metabolites, phosphotransferase system (PTS), starch and sucrose metabolism and microbial metabolism in diverse environments, indicating that bacteriocin PCM7-4 mainly affects the expression of genes related to biosynthesis of secondary metabolites, phosphotransferase system (PTS) and starch and sucrose metabolism of Listeria monocytogenes.
[0092] (5) RT-PCR verification
[0093] The above RNA-Seq results were verified by RT-PCR. Total RNA was extracted using RNAiso Plus reagent and reverse transcribed into cDNA using PrimeScript™ RT kit. The PCR amplification reaction system was prepared according to the instructions of TB Green® Premix Ex Taq™ II, using 16S rRNA as the internal reference gene. To further verify the transcriptome sequencing results, five ascending and five descending differentially expressed genes were randomly selected for RT-qPCR.
[0094] The results are as follows Fig.13 As shown, the reliability of the RNA-seq results was demonstrated. Transcriptome analysis and verification showed that bacteriocin PCM7-4 mainly affected the expression of genes related to the biosynthesis of secondary metabolites, phosphotransferase system (PTS), and starch and sucrose metabolism of Listeria monocytogenes.
[0095] In summary, the present invention isolated and identified a strain of Bacillus Velezii ( Bacillus velezensis ) CM7-4 strain, which has a broad-spectrum antibacterial activity and can inhibit a variety of pathogens, and has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, Salmonella, Enterobacter aerogenes, Pasteurella multocida, Enterococcus faecalis, Staphylococcus aureus and Listeria monocytogenes; at the same time, a new bacteriocin was isolated from the CM7-4 strain, named PCM7-4. Through purification and determination, the molecular weight of bacteriocin PCM7-4 was 14.3 KDa, which is heat-resistant and has a pH of 1. It is highly stable in the range of 2-12, sensitive to proteinase K, and has no hemolytic activity; and bacteriocin PCM7-4 has a significant inhibitory effect on Listeria monocytogenes, with an MIC of 5.625μg / mL for Listeria monocytogenes, and can inhibit the formation of Listeria monocytogenes biofilm; further transcriptome analysis and verification showed that bacteriocin PCM7-4 mainly affects the biosynthesis of secondary metabolites of Listeria monocytogenes, the expression of genes related to the phosphotransferase system (PTS), and starch and sucrose metabolism. These results indicate that bacteriocin PCM7-4 prepared by Bacillus Velez CM7-4 strain has great potential as a new antibacterial drug.
[0096] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. A strain of Bacillus velez Bacillus velezensis ) CM7-4 strain, characterized in that The strain was deposited in the Guangdong Provincial Microbiological Culture Collection Center on July 16, 2024, with the collection number GDMCC No: 64872.
2. Use of the CM7-4 strain or its bacterial solution according to claim 1 in the preparation of bacteriocin.
3. The use of the CM7-4 strain or its bacterial solution according to claim 1 in inhibiting pathogenic bacteria for non-disease diagnosis and treatment purposes, characterized in that: The pathogen is Escherichia coli ( Escherichia coli ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ),salmonella( Salmonella )、Enterobacter aerogenes( Enterobacter aerogenes ), Pasteurella multocida ( Pasteurella multocida ), Enterococcus faecalis ( Enterococcus faecalis ), Staphylococcus aureus ( Staphylococcus aureus ), Listeria monocytogenes ( Listeria monocytogenes ) 4. Use of the CM7-4 strain or its bacterial solution according to claim 1 in the preparation of an antibacterial agent, characterized in that: The pathogenic bacteria inhibited by the antibacterial agent are Escherichia coli ( Escherichia coli ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ),salmonella( Salmonella )、Enterobacter aerogenes( Enterobacter aerogenes ), Pasteurella multocida ( Pasteurella multocida ), Enterococcus faecalis ( Enterococcus faecalis ), Staphylococcus aureus ( Staphylococcus aureus ), Listeria monocytogenes ( Listeria monocytogenes ) 5. An antibacterial agent, characterized in that Containing the CM7-4 strain or its bacterial solution as claimed in claim 1.
6. A crude bacteriocin extract, characterized in that First, the CM7-4 strain described in claim 1 is inoculated into LB broth and cultured at 37°C for 16 h, and then inoculated into a fermentation medium at a 2% inoculum, and cultured at 30°C and 180 rpm for 24 h; after fermentation, the supernatant is collected by centrifugation at 8000 rpm for 30 min at 4°C, and the cell-free supernatant is obtained after sterilization by filtration through a 0.22 μm filter membrane; the cell-free supernatant is adjusted to pH 2.0 with 6 mol / L HCl, and allowed to stand at 4°C overnight, and then centrifuged at 4°C and 8000 rpm for 30 min to collect the precipitate; finally, the precipitate is re-dissolved with PBS, and sterilized by filtration through a 0.22 μm filter membrane to obtain a crude bacteriocin extract; The fermentation medium formula is: 4.0 g glucose, 0.5 g beef extract, 0.5 g yeast extract powder, 1.5 g peptone, 0.02 g NaH2PO4·2H2O, 0.05 g Na2HPO4·2H2O, 0.05 g Mg2SO4·7H2O, 0.02 g CaCl2, 0.02 g MnSO4, and 100 mL distilled water.
7. The crude bacteriocin extract of claim 6 is used for the purpose of non-disease diagnosis and treatment against Listeria monocytogenes ( Listeria monocytogenes ) in applications.
8. Use of the crude bacteriocin extract according to claim 6 in the preparation of antibacterial drugs, characterized in that: The pathogenic bacteria of the antibacterial drug are Escherichia coli ( Escherichia coli ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ),salmonella( Salmonella )、Enterobacter aerogenes( Enterobacter aerogenes ), Pasteurella multocida ( Pasteurella multocida ), Enterococcus faecalis ( Enterococcus faecalis ), Staphylococcus aureus ( Staphylococcus aureus ), Listeria monocytogenes ( Listeria monocytogenes )
Citation Information
Patent Citations
Safe and nontoxic Bacillus velezensis PH6 strain capable of specifically inhibiting MRSA and application thereof
CN112375710A
Salt-tolerant bacillus velezensis with high yield of lipopeptide and application of bacillus velezensis
CN114317317A
Antibacterial lipopeptide produced by bacillus velezensis and application of antibacterial lipopeptide in cosmetics and food
CN115044505A
Bacillus velezensis 1-3, method for simultaneously producing two types of antibacterial substances by bacterial strain, antibacterial substances produced by bacterial strain and application of antibacterial substances
CN116218701A
Novel bacillus velezensis with antivacterial activity for antibiotics resistant enterobacteia
KR102613646B1
